antibody-mediated immunotherapy macaques chronically infected shiv suppresses viraemia
neutralizing antibodies can confer immunity primate lentiviruses blocking infection macaque models aids- however earlier studies anti-human immunodeficiency virus type hiv- neutralizing antibodies administered infected individuals humanized mice reported poor control virus replication rapid emergence resistant variants- new generation anti-hiv monoclonal antibodies possessing extraordinary potency breadth neutralizing activity recently isolated infected individuals neutralizing antibodies target different regions hiv envelope glycoprotein including cd4-binding site glycans located v1/v2 v3 v4 regions membrane proximal external region gp41 refs examined two new antibodies directed cd4-binding site v3 region 3bnc117 respectively ability block infection suppress viraemia macaques infected r5 tropic simian-human immunodeficiency virus shiv-ad8 emulates many pathogenic immunogenic properties hiv infections rhesus macaques either antibody alone can potently block virus acquisition administered individually recently infected macaques antibody caused rapid decline virus load undetectable levels days followed virus rebound neutralization-resistant variants became detectable administered together single treatment rapidly suppressed plasma viraemia weeks long-term chronically shiv-infected animals low cd41 t-cell levels second cycle anti-hiv monoclonal antibody therapy administered two previously treated animals successfully controlled virus rebound results indicate immunotherapy combination immunotherapy plus conventional antiretroviral drugs might useful treatment chronically hiv--infected individuals experiencing immune dysfunction
